Top Page
Senzime AB
(OTC:SEZI)
Senzime AB (SEZI) vs. iShares MSCI Sweden ETF (EWD)
Senzime AB Business Overview & Revenue Model
Senzime AB Earnings Call Summary
Senzime AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 80.63M | 58.48M | 35.75M | 14.03M | 10.98M | 9.34M |
| Gross Profit | 32.92M | 20.12M | 8.34M | -4.39M | -4.92M | -7.90M |
| EBITDA | -84.03M | -95.53M | -118.82M | -120.05M | -73.20M | -36.96M |
| Net Income | -126.40M | -118.73M | -134.15M | -132.70M | -82.14M | -47.45M |
Balance Sheet | ||||||
| Total Assets | 435.22M | 424.53M | 433.54M | 322.68M | 174.62M | 258.89M |
| Cash, Cash Equivalents and Short-Term Investments | 132.16M | 100.94M | 151.01M | 26.04M | 74.87M | 160.31M |
| Total Debt | 14.94M | 22.67M | 11.47M | 13.04M | 1.63M | 2.40M |
| Total Liabilities | 63.82M | 78.67M | 58.06M | 60.78M | 24.04M | 27.55M |
| Stockholders Equity | 371.40M | 345.86M | 375.48M | 261.90M | 150.58M | 231.35M |
Cash Flow | ||||||
| Free Cash Flow | -125.35M | -126.28M | -121.73M | -141.89M | -84.30M | -38.66M |
| Operating Cash Flow | -103.29M | -105.94M | -113.91M | -136.78M | -81.33M | -38.34M |
| Investing Cash Flow | -22.06M | -20.34M | -7.82M | -4.98M | -2.97M | -327.00K |
| Financing Cash Flow | 177.55M | 75.86M | 246.51M | 92.36M | -945.00K | 167.69M |
Senzime AB Technical Analysis
Senzime AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | kr1.01B | 39.26 | 7.56% | ― | -10.34% | -59.69% | |
57 Neutral | kr1.59B | -31.31 | -23.20% | ― | 36.23% | 63.14% | |
48 Neutral | kr1.23B | -24.11 | -5.53% | ― | 16.27% | -22.61% | |
45 Neutral | kr714.90M | -38.78 | -5.96% | ― | 11.60% | 75.76% | |
43 Neutral | kr988.88M | ― | -35.36% | ― | 71.41% | 17.26% | |
43 Neutral | kr293.13M | -8.98 | -18.68% | ― | -5.63% | -1373.99% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Senzime AB Corporate Events
Senzime has achieved a significant milestone by securing the installation of its TetraGraph system across all sites of a top-ranked US hospital system. This expansion is expected to impact approximately 15,000 patients annually, reinforcing Senzime’s position in the market and aligning with clinical guidelines for neuromuscular monitoring. The TetraGraph system, developed through over 40 years of research, offers proprietary capabilities that enhance patient safety and compliance with clinical standards.
Senzime AB has increased its total number of shares to 157,215,046 following a directed share issue of 700,000 shares. This move reflects the company’s strategic efforts to strengthen its financial position and potentially expand its influence in the medical device industry, aligning with its commitment to advancing patient safety and operational efficiency.
Senzime has received regulatory approval from the Mexican Secretariat of Health for its TetraGraph system, allowing its commercialization in Mexico. This approval opens up significant market opportunities in a region that follows US and European clinical guidelines, supported by a partnership with Kezelmedica, a prominent importer of medical devices in Mexico.
Senzime AB has successfully completed the full subscription of its directed share issue, raising MSEK 110 through the issuance of 24,000,000 shares. This capital increase will support the company’s growth, resulting in a 15.27% dilution of shares, and reflects strong investor confidence in Senzime’s market position and future prospects.
Senzime AB announced that its licensee, Fukuda Denshi, has obtained FDA and UKCA approvals to introduce the HN-100 neuromuscular transmission module in the US and UK. This development is significant for Senzime as it expands Fukuda’s market reach, leveraging Senzime’s TetraGraph® technology, and potentially increasing revenue through manufacturing and royalty agreements.
Senzime AB has announced a webcast presentation of its second quarter 2025 financial report, scheduled for July 18. The presentation, led by CEO Philip Siberg, will provide insights into the company’s performance and will include a Q&A session, reflecting Senzime’s commitment to transparency and engagement with investors and stakeholders.
Senzime AB has secured a significant contract with a major U.S. university hospital system to supply its TetraGraph monitors and engage in scientific collaboration. This agreement, which involves the installation of 63 monitors in Texas, aims to standardize neuromuscular monitoring for over 27,000 patients annually. The collaboration will leverage Senzime’s TetraConnect platform and AI analysis to enhance anesthesia care through personalized, data-driven approaches. This milestone not only represents one of Senzime’s largest installations but also sets a benchmark for implementing Quality Improvement initiatives in anesthesiology, potentially transforming patient monitoring and management during surgery.
Senzime AB has been granted a new U.S. patent for its TetraGraph system, which enhances the system’s capabilities by improving the quality of electromyography signals. This patent strengthens Senzime’s competitive position in the neuromuscular monitoring field, highlighting their commitment to innovation and patient safety.
Senzime AB held an extraordinary general meeting where shareholders unanimously approved a directed share issue, allowing Adam Dahlberg to subscribe for up to 700,000 new shares at SEK 4.60 each. This decision will increase the company’s share capital by a maximum of SEK 87,500, potentially impacting its financial structure and market positioning.
Senzime AB has completed the first tranche of its directed share issue, successfully allocating 22,250,000 out of 23,300,000 shares, resulting in a capital increase of approximately MSEK 102.38. This move, involving new and long-term institutional investors, aims to bolster the company’s financial standing and expand its shareholder base, with the second tranche pending approval at an extraordinary general meeting.
Senzime AB has announced an extraordinary general meeting to be held on June 30, 2025, to approve a directed share issue. This strategic move aims to inject new capital into the company by issuing a maximum of 700,000 new shares, specifically directed to Adam Dahlberg, to strengthen its financial position and support its growth initiatives.
Senzime AB has announced a directed share issue to raise SEK 110 million, aimed at supporting its commercial expansion, innovation projects, and working capital needs. The share issue involves new and existing investors, including significant institutional investors, and is intended to strengthen the company’s shareholder base, providing increased security and stability. The decision to opt for a share issue over loan financing reflects the company’s strategic focus on cost efficiency and investor support.
Senzime AB welcomes the pre-announcement of new European pediatric guidelines for quantitative neuromuscular monitoring during anesthesia, revealed at the Euroanaesthesia 2025 congress. This development is significant for pediatric anesthesia, as it recommends EMG-based monitoring technology, aligning with Senzime’s TetraGraph system, which is FDA-cleared for use on patients as young as one month. The guidelines represent a substantial market opportunity for Senzime, addressing the historical lack of specialized pediatric solutions and aiming to reduce the risks of residual neuromuscular block in pediatric surgeries.
Senzime AB’s annual general meeting resulted in several key resolutions, including the adoption of the 2024 financial statements, re-election of board members, and the introduction of a new employee stock option program. These decisions aim to strengthen the company’s governance and incentivize its workforce, potentially enhancing its market position and operational effectiveness.